



June 2009

Volume 9, Number 6



INMD Update

Contact INMD

Dr. Philip Sherman
Scientific Director
sd.inmd@sickkids.ca

Mary-Jo Makarchuk, MHS
Assistant Director, Toronto
416-978-1324
mary-jo.makarchuk@sickkids.ca

Vera Ndaba
Business Officer and Event Planner
416-978-1326
vera.ndaba@sickkids.ca

Alexandra Novis
Executive Assistant
416-978-1315
alexandra.novis@sickkids.ca

Paul Bélanger,
B.Sc.N
Assistant Director, Ottawa
613-946-6465
paul.belanger@cihr-irsc.gc.ca

Melanie Bergeron
Project Officer, Ottawa
613-941-3504
melanie.bergeron@cihr-irsc.gc.ca

Toronto Mailing Address:
CIHR-INMD
University of Toronto
Banting Building, Room 207L
100 College St.
Toronto, ON, M5G 1L5

Ottawa Mailing Address:
CIHR Corporate Headquarters
Room 97 160 Elgin St.
Address Locator 4809A
Ottawa, ON, K1A 0W9



Message from Dr. Phil Sherman, SD

(photographed with Dr. Eve Roberts IAB chair)

On June 12 and 13, the Institute of Nutrition, Metabolism, and Diabetes (INMD) Institute Advisory Board (IAB) met in Quebec City. We were delighted that Dr. Steve James, Director of the Digestive Diseases and Nutrition section of the National Institutes of Diabetes, Digestive and Kidney Disease (NIDDK) at the National Institutes of Health in Washington, DC, kindly agreed to attend the IAB meeting as a guest speaker. Dr. James

provided insights about the development of a strategic plan for Liver and Digestive Disease research from the NIDDK perspective, and highlighted points of relevance for consideration by the IAB in recommending strategic priorities for our Institute. IAB members were engaged in the presentation and ensuing discussions, which included an exercise to identify mechanisms and criteria that will be used to set research and knowledge translation strategic priorities at the November meeting of the IAB. Relevant presentations on Knowledge Translation and Ethics, essential components of the updated INMD strategic plan, were also featured at the IAB meeting.

To support the development of the updated strategic plan, an important project which INMD has undertaken is an assessment of the previous focus in the area of obesity and healthy body weight. Such an evaluation is consistent with the CIHR's new *Health Research Roadmap*, which emphasizes the need for demonstrating impacts of health research. A review of the preliminary results of this analysis was shared with the IAB. To complement the presentation, Dr. Denis Richard from the Université de Laval described how his research group is approaching obesity and its complications through both specific research endeavours and capacity building in the field.

I strongly encourage you to check the CIHR website periodically for new announcements that may prove of interest to you and your research collaborators. Please contact us to let me know how we are doing so that I may work to serve your needs and goals in my capacity as a Scientific Director at the CIHR.

Best wishes for the summer holiday season,

Philip M. Sherman, MD, FRCPC

INMD Scientific Director



IAB Quebec City

CIHR NEWS

Researcher News

[click here](#)


Upcoming Events

11th Symposium of the
International Diabetes
Epidemiology Group
Le Château Frontenac,
Québec City, Canada
October 15-18, 2009

[click here](#)

INMD MANDATE

The Institute of Nutrition, Metabolism and Diabetes supports research to enhance health in relation to diet, digestion, excretion, and metabolism; and to address causes, prevention, screening, diagnosis, treatment, support systems, and palliation for a wide range of conditions and problems associated with hormone, digestive system, kidney, and liver function.



INMD Partners on Isotope Initiative

The Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Council of Canada (NSERC) are providing \$6 million in research funding to find alternatives to the medical isotopes that are affected by the current shutdown at the Chalk River nuclear reactor.

In addition, the funding opportunity will support research on alternative means of ^{99m}Tc production that do not require the use of a nuclear reactor and that are likely to yield clinically useful Technetium-labeled radiopharmaceuticals within the two year granting period. It is expected that this funding opportunity will lead to clinical trials applications and small scale clinical validation studies which compare the novel radio labeled probes with those in current practice. For more information about this funding opportunity [click here](#)

Changes to Randomized Controlled Trials

Effective June 2009, the Randomized Controlled Trials (RCT) Program will be integrated in the Open Operating Grants Program (OOGP). Please refer to the Open Operating Grants 2009-2010 funding opportunity on the CIHR Website for program specific details when the new version is launched in late June. For applications to the Open Operating Grants Program for Randomized Controlled Trials there will be two possibilities: 1) if the budget requested is less than \$250,000 in every project year researchers may apply to the most relevant content peer review committee or to the RCT peer review committee; and, 2) if the budget requested is greater than or equal to \$250,000 in any project year researchers must apply to the RCT peer review committee.

CIHR staff will decide on the most appropriate review committee, whether ad hoc or an existing review committee, for the review of these applications.

IAB Members Moving On

INMD staff and Advisory Board members bid farewell recently to three departing colleagues, who have completed their terms: Lise Dubois, from the University of Ottawa (pictured) John Harnett, from the University of Newfoundland and co-chair of Research Council, Kidney Foundation of Canada, and Sylvie Ekstrand-Robichaud, from University of Moncton, Director of Nursing. We at the Institute of Nutrition, Metabolism and Diabetes, would like to take this opportunity to thank these individuals once again for their dedication and commitment, and wish them all the best in their future endeavours.



Feedback on the INMD Newsletter

Help us serve you better by emailing INMDComms@cihr-irsc.gc.ca and let us know what you would like to read about in the future. To [subscribe](#) to this newsletter, please email INMDComms@cihr-irsc.gc.ca and type "subscribe" in the subject line. To [unsubscribe](#), please email INMDComms@cihr-irsc.gc.ca and type "unsubscribe" in the subject line.